Deep vein thrombosis (DVT) is a common complication of paraplegia despite prophylactic anticoagulant therapy. The diagnosis relies primarily on ultrasonography or phlebography; these investigations are dicult, expensive and can be time-consuming in paraplegic patients. Study Design: To evaluate the usefulness of coagulation activation markers in excluding a diagnosis of DVT, D-Dimers, thrombin-antithrombin complexes, prothrombin fragments (F 1+2 ) and activated factor VIIa. Objectives: To improve the diagnosis of deep venous thrombosis in paraplegic patients. Setting: This collaborative work was done at Raymond PoincareÂ Hospital, Garches, France. Methods: To evaluate the usefulness of coagulation activation markers in excluding a diagnosis of DVT, D-Dimers (D-Di), thrombin-antithrombin (TAT) complexes, prothrombin fragments (F 1+2 ) and activated factor VIIa (FVIIa), were determined in a prospective study of 67 consecutive patients with paraplegia or tetraplegia. Doppler ultrasonography and/or phlebography of the lower limbs and D-Di, TAT, F 1+2 level determination were systematically done in each patient at admission to our rehabilitation unit. Results: Despite prophylactic low molecular weight heparin therapy, six of the 67 patients developed DVT diagnosed by radiologic explorations. D-Di levels measured by a reference ELISA (Asserachrom D-Di, Diagnostica Stago) or a new rapid automated turbidimetric test (STA-Liatest D-Di) were greater than 500 ng/ml in all DVT patients and in 40 non-DVT patients, of whom most had urinary tract infections, osteomas, or pressure sores. D-Di values were normal in only 21/67 patients (31%). The negative predictive value of D-Di in our study was 100% since all DVT patients had D-Di values greater than 500 ng/ml. TAT and F 1+2 levels were not correlated with D-Di levels but also had a negative predictive value of 100%. Comparison of D-Di levels obtained using the two tests showed that results of the reference ELISA were closely correlated to those of the new rapid automated turbidimetric. TAT, F 1+2 , and factor VIIa are not useful for measuring hypercoagulability in paraplegic or tetraplegic patients since no rapid tests for determining these parameters are available. Conclusion: D-Di levels determined using an ELISA or a new rapid automated turbidimetric test have a good negative predictive value for DVT in paraplegic or tetraplegic patients and may reduce the need for Doppler ultrasonography and/or phlebography by 31%.
Introduction
Deep vein thrombosis (DVT) and pulmonary embolism (PE) remain common complications of spinal cord injury 1 despite widespread use of prophylactic anticoagulant therapy. 2, 3 The clinical diagnosis of venous thrombosis is extremely dicult in such patients and the prevalence of thromboembolic complications has varied across studies, 4, 5 in particular as a result of dierences in diagnostic methods; in the great majority of the cases, radiologic explorations are necessary particularly ultrasonography and/or phlebography. Over the last few years, several markers for coagulation activation and ®brinolysis have been identi®ed. Among them, plasma D-Dimer (D-Di) levels determined using an ELISA oer high sensitivity (97%) and negative predictive value (95%) for excluding venous thromboembolism in ambulatory patients and pulmonary embolism. 6 ± 9 Plasma D-Di is a cross-linked ®brin degradation product that re¯ects ®brin formation and subsequent dissolution. In a previous study, 10 we evaluated haemostatic function, endothelial reactivity, and coagulation activation in patients with traumarelated paraplegia or tetraplegia. We found that prolonged bedrest was not associated with the recovery of ®brinolytic activity, and that D-Di levels were increased in 70% of DVT patients and in many non-DVT patients with conditions such as pressure sores, infections, or osteomas.
To our knowledge, the usefulness of D-Di levels for ruling out DVT in patients with paraplegia or tetraplegia has not yet been studied. Our goal was to determine the negative predictive value of D-Di for DVT in 67 paraplegic or tetraplegic patients comparatively to Doppler ultrasonography and/or phlebography. We also measured three other markers for coagulation activation, namely thrombin antithrombin (TAT) complexes, prothrombin fragments (F 1+2 ) and activated factor VIIa. Because the reference ELISA for D-Di level determination is too timeconsuming to be useful in emergencies, we compared D-Di levels obtained using the classic ELISA (Asserachrom D-Di, Diagnostica Stago, AsnieÁ res, France) and a fast new D-Di assay (STA-Liatest DDi, Diagnostica Stago). We then determined if these two assays provided a greater than 95% negative predictive value for DVT.
Methods

Patients
Sixty-seven consecutive patients with paraplegia or tetraplegia (52 males and 15 females) aged 17 ± 72 years were included in this prospective study. The 59 patients with paraplegia of 1 ± 6 months duration were receiving prophylactic low molecular weight heparin therapy, whereas the eight patients with longer paralysis durations were not. Written informed consent was obtained from each patient prior to study inclusion, and the study was conducted in accordance with the Declaration of Helsinki and with French legislation on biomedical research studies in humans. Doppler ultrasonography of the lower limbs and haemostasis tests including D-Di, F 1+2 and FVIIa level determination were systematically done in each patient at admission to our rehabilitation unit. This screening was systematically performed for patients on hospital admission.
Blood samples
Venous blood was drawn directly into tubes containing EDTA 0.17 M for blood cell counts, tubes containing sodium citrate 0.129 M (1 vol/9 vol) (Vacutainer, Becton Dickinson, France) for haemostasis parameter determination, and Diatubes (Venoject) containing trisodium citrate 0.11 M, theophylline 15 nM, adenosine 37 nM, and dipyridamole 0.198 nM for TAT and F 1+2 determination. Platelet-poor plasma obtained by blood centrifugation at 2700 g for 20 min at 158C within 1 h of sampling was divided in 1 ml aliquots and frozen at 7808C. Coagulation tests were performed within 1 month after blood sampling, except ®brinogen and D-Di determination, which were done on fresh platelet-poor plasma immediately after centrifugation.
Imaging studies and blood tests Ultrasonography with pulsed color¯ow Doppler was performed at the time of blood sampling for the coagulation study, using the same ultrasound unit (Acuson XP 128) in all patients. The venous system was examined between the vena cava and the ankle veins. Enlargement, absence of compressibility, absence of a color Doppler signal, or direct visualisation of the thrombus were considered to indicate venous thrombosis. Patients whose veins were not completely visualised by Doppler ultrasonography underwent phlebography done using a conventional technique involving insertion of butter¯y needles into the dorsal vein of each foot. A non-ionic contrast medium (Omnipaque-Nycomed Imaging Norway or Iopamiron-Schering Imaging Germany) was injected via a power injector. Tourniquets were used to improve opaci®cation of the deep veins.
Blood cell and platelet counts were determined using an automated counter (MaxM, Coultronics, Margency, France). All clotting parameter determinations including factor VIIa (Staclot VIIa-rTF, Diagnostica Stago, France) were performed using a fully automated apparatus (STA, Diagnostica Stago, France). Prothrombin time, activated partial prothrombin time were respectively performed with Neoplastin CI and PTTA reagent (Diagnostica Stago). Fibrinogen was assayed using the Clauss method (Fibriprest A, Diagnostica Stago), with results in mg/dl. TAT and F 1+2 were assayed using an ELISA (Enzygnost TAT and Enzygnost F 1+2 respectively, from Dade-Behring, Paris la DeÂ fense, The radiologists were unaware of laboratory test results, and the laboratory technicians were unaware of imaging study ®ndings. Statistical evaluation of the data involved Student's t-test done using the Statgraphics system (Uniware).
Results
Patient characteristics
Mean age was 34 years with a range of 17 ± 72; 84% of patients were younger than 30 years. Over three-quarters of the patients were males (77%). Eighty-eight per cent of patients were on prophylactic anticoagulant therapy, usually consisting in a low molecular weight heparin. Fifty patients had paraplegia and 17 tetraplegia, with injury being the most common cause. Six of the 67 patients (9%) developed DVT diagnosed by Doppler ultrasonography; three out of these six patients underwent a phlebography which con®rmed the diagnosis of DVT done by ultrasonography. All six were on prophylactic low molecular weight heparin therapy at the time of the DVT.
Platelet count were in the normal range (304+140 10 9 /1). The clotting parameters results were the following: (mean+standard deviation) prothrombin time 91+9%, activated partial prothrombin time 35+4.5 seconds, ®brinogen 4.3+1.5 mg/dl, factor VIIa 43+22 mUI/ml (normal: 5 ± 85 mUI/ml).
Markers for coagulation activation D-Di levels by the reference assay (Asserachrom D-Di) were below 500 ng/ml in 21 patients and increased (4500 ng/ml) in 46, including six with DVT and 40 without DVT (Table 1) . Many of the non-DVT patients had urinary tract infection, pressure sores, or osteoma. The negative predictive value of D-Di for DVT was 100%.
TAT and F 1+2 were normal in 60% of patients. No correlation was found between TAT and F 1+2 levels ( Figure 1 ). Neither were TAT or F 1+2 levels correlated with D-Di levels. All the DVT patients had elevated levels of TAT, F 1+2 , and factor VIIa, yielding a negative predictive value for DVT of 100% for each of these three markers.
Using D-Di, TAT, F 1+2 , and VIIa in combination did not provide a useful increase in the positive predictive value, and retained a negative predictive value of 100%. Table 2 shows the regression curve slopes and coecients of correlation for the Liatest D-Di kit versus the reference ELISA. When D-Di levels were below 500 ng/ml, levels by the Liatest D-Di were lower (slope 0.91) overall than those obtained using the Asserachrom D-Di kit. Results were discordant in three patients (500, 440, and 310 ng/ml, respectively, by the Asserachrom D-Di versus 760, 1060, and 540 ng/ ml, respectively, by the Liatest D-Di); none of whom had DVT. When the levels were greater than 500 ng/ ml, levels by the Liatest D-Di were higher (slope 1.6) than levels by the Asserachrom D-Di.
Comparison of D-Di levels with the Asserachrom D-Di and Liatest D-Di kits
Discussion
DVT and PE are complications of spinal cord injury that occur predominantly during the ®rst 2 ± 3 months and are major causes of morbidity and mortality. 12 The diagnostic value of D-Di in thromboembolic disorders has been recognised for more than two decades. The negative predictive value of D-Di for DVT has been studied by a number of investigators.
11,13 ± 15 In our previous study, 10 we showed that 70% of paraplegic patients had high D-Di levels, and that D-Di levels were signi®cantly increased not only in DVT but also in other conditions such as pressure sores, osteomas, and infections. Elevated D-Di levels in DVT suggest persistence of the thrombotic process without recovery of a normal ®brinolytic potential. Spinal cord injury is associated with several risk factors for DVT. In particular, slowing of the venous blood¯ow due to in¯ammation and absence of muscle contractions promote venous thrombosis and pulmonary embolism. 16, 17 The two aims of this study were to evaluate D-Di and other coagulation activation markers for excluding DVT in patients with paraplegia or tetraplegia and to determine if a rapid, quantitative, and automated D-Di test that provides results within 1 h could be used. Rapid D-Di tests including sensitive latex assays and faster ELISAs or ELISA-derived assays have been developed to allow D-Di determination in emergencies.
18 ± 20 STA-Liatest is a fast (10 min) automated turbidimetric test involving use of latex beads coated with two monoclonal D-Di antibodies that agglutinate in the presence of D-Di.
The negative predictive value of D-Di levels in our prospective study of 67 consecutive patients with paraplegia or tetraplegia was evaluated based on the results of a reference ELISA. D-Di levels were compared to ®ndings from a Doppler ultrasonography and/or phlebography, as well as to levels of other coagulation activation markers, namely thrombin antithrombin (TAT), prothrombin fragments (F 1+2 ), and factor VIIa. Doppler ultrasonography has demonstrated good sensitivity and speci®city versus phlebography for the detection of DVT. 21, 22 The reference ELISA (Asserachrom D-Di) was found to have a negative predictive value of 100%, which is in keeping with earlier studies. 8, 9 Correlations were strong between the reference test and the STALiatest D-Di. In three patients, none of whom had DVT, a discrepancy was noted between the D-Di levels obtained using the reference Asserachrom D-Di test and the STA Liatest D-Di test. The slope of the regression curve between these two tests was smaller than one when D-Di levels were under 500 ng/ml but far larger than one when D-Di levels were greater than 500 ng/ml. These ®ndings suggest that a cut-o smaller than 500 ng/ml may be appropriate for the STALiatest test, and that studies in a larger number of patients are warranted to investigate this issue.
TAT, F 1+2 and FVIIa levels were not correlated with D-Di levels, but each had a negative predictive value of 100% for DVT. Using TAT, F 1+2 , and/or VIIa alone or in combination failed to provide a useful increase in positive predictive value. Although TAT and F 1+2 measure hypercoagulability in spinal cord injury patients, they cannot be used in the emergency diagnosis of thrombosis since no rapid assay is available for either marker.
In conclusion, D-Di is a useful marker for DVT in patients with paraplegia or tetraplegia. D-Di assay such as STA-Liatest D-Di is a fast and reliable test that can be used for ruling out DVT on an emergency basis. In our study D-Di level determination had a negative predictive value for DVT of 100% and would have obviated the need for Doppler ultrasonography and/or phlebography in 31% of cases.
